Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
May 3 REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
May 3 REGN Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
May 3 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
May 3 REGN Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
May 2 KOD Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
May 2 REGN Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript
May 2 REGN Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
May 2 REGN Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
May 2 OTLK Outlook Therapeutics® to Present at the Retina World Congress 2024
May 2 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
May 2 REGN Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 2 REGN Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
May 2 REGN Regeneron falls after Q1 miss; announces $3B share buybacks
May 2 REGN 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 REGN Regeneron Earnings Miss; Biotech Giant's Stock Falls
May 2 REGN Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook
May 2 REGN Regeneron Reports First Quarter 2024 Financial and Operating Results
May 1 REGN Regeneron Pharmaceuticals Q1 2024 Earnings Preview
May 1 BNTC Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 1 REGN Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags